[{"id":"0206427b-6413-49b4-a589-ddaddbc55f24","acronym":"","url":"https://clinicaltrials.gov/study/NCT00050752","created_at":"2021-01-18T00:05:26.913Z","updated_at":"2025-02-25T13:38:46.395Z","phase":"","brief_title":"Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer","source_id_and_acronym":"NCT00050752","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FH","pipe":" | ","alterations":" FH mutation","tags":["FH"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FH mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 02/24/2003","start_date":" 02/24/2003","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"48df85e5-b786-45f4-a391-eab53ca69d44","acronym":"AMPLIFY","url":"https://clinicaltrials.gov/study/NCT04000880","created_at":"2024-02-21T19:24:47.029Z","updated_at":"2025-02-25T13:48:43.597Z","phase":"","brief_title":"Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health","source_id_and_acronym":"NCT04000880 - AMPLIFY","lead_sponsor":"University of Alabama at Birmingham","biomarkers":" IL6 • TNFA • CRP","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 603","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2025-02-21"},{"id":"c2c0bdf4-79cd-4e7d-b1f6-9bf7bf2f7d00","acronym":"SAVOIR","url":"https://clinicaltrials.gov/study/NCT03091192","created_at":"2021-01-17T17:49:25.734Z","updated_at":"2025-02-25T15:10:33.304Z","phase":"Phase 3","brief_title":"Savolitinib vs. Sunitinib in MET-driven PRCC.","source_id_and_acronym":"NCT03091192 - SAVOIR","lead_sponsor":"AstraZeneca","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Orpathys (savolitinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 07/25/2017","start_date":" 07/25/2017","primary_txt":" Primary completion: 08/18/2019","primary_completion_date":" 08/18/2019","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-13"},{"id":"12b710b2-1109-43fb-8b55-f68f0578591b","acronym":"FIT-001","url":"https://clinicaltrials.gov/study/NCT06026410","created_at":"2023-09-07T16:09:33.674Z","updated_at":"2025-02-25T14:18:15.893Z","phase":"Phase 1","brief_title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","source_id_and_acronym":"NCT06026410 - FIT-001","lead_sponsor":"Kura Oncology, Inc.","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • HRAS mutation","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • HRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Krazati (adagrasib) • darlifarnib (KO-2806)"],"overall_status":"Recruiting","enrollment":" Enrollment 270","initiation":"Initiation: 10/18/2023","start_date":" 10/18/2023","primary_txt":" Primary completion: 01/01/2027","primary_completion_date":" 01/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2025-02-12"},{"id":"56bb338a-9a55-47ed-87d8-9a54d97136da","acronym":"","url":"https://clinicaltrials.gov/study/NCT03595124","created_at":"2021-01-18T17:40:40.562Z","updated_at":"2025-02-25T16:31:25.872Z","phase":"Phase 2","brief_title":"A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)","source_id_and_acronym":"NCT03595124","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • PD-1 • CD38 • PTPRC • CD69 • TFE3 • CD14 • CD24 • ITGAM • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • axitinib • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 01/23/2026","study_completion_date":" 01/23/2026","last_update_posted":"2025-02-07"},{"id":"2aac339a-fbd4-48aa-9c04-5e7a6adc7234","acronym":"NCI-MATCH","url":"https://clinicaltrials.gov/study/NCT02465060","created_at":"2021-01-17T17:15:30.769Z","updated_at":"2025-02-25T16:36:36.993Z","phase":"Phase 2","brief_title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","source_id_and_acronym":"NCT02465060 - NCI-MATCH","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSI • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["MSI • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Mekinist (trametinib) • cisplatin • Xalkori (crizotinib) • Tagrisso (osimertinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Imbruvica (ibrutinib) • gemcitabine • paclitaxel • Rituxan (rituximab) • docetaxel • 5-fluorouracil • sunitinib • everolimus • Vectibix (panitumumab) • temozolomide • Koselugo (selumetinib) • Perjeta (pertuzumab) • cytarabine • Kadcyla (ado-trastuzumab emtansine) • bortezomib • doxorubicin hydrochloride • Talzenna (talazoparib) • capecitabine • Piqray (alpelisib) • Xtandi (enzalutamide) • azacitidine • Cabometyx (cabozantinib tablet) • Balversa (erdafitinib) • Gazyva (obinutuzumab) • Mektovi (binimetinib) • albumin-bound paclitaxel • cyclophosphamide • Imjudo (tremelimumab-actl) • Cyramza (ramucirumab) • pemetrexed • fulvestrant • oxaliplatin • adavosertib (AZD1775) • etoposide IV • irinotecan • Halaven (eribulin mesylate) • Xpovio (selinexor) • Conmana (icotinib) • Pemazyre (pemigatinib) • Truqap (capivasertib) • methotrexate • Zarnestra (tipifarnib) • Aliqopa (copanlisib) • fexagratinib (ABSK091) • Ninlaro (ixazomib) • pegylated liposomal doxorubicin • epirubicin • sapanisertib (CB-228) • ipatasertib (RG7440) • Caprelsa (vandetanib) • vincristine • vinorelbine tartrate • Cometriq (cabozantinib capsule) • Tabrecta (capmatinib) • spartalizumab (PDR001) • taselisib (GDC-0032) • daunorubicin • omipalisib (GSK2126458) • ulixertinib (BVD-523) • mitoxantrone • Erivedge (vismodegib) • carmustine • bendamustine • bicalutamide • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Zepzelca (lurbinectedin) • mitomycin • Jingzhuda (entinostat) • Recentin (cediranib) • Trazimera (trastuzumab-qyyp) • melphalan • Fakzynja (defactinib) • GSK2636771 • Zirabev (bevacizumab-bvzr) • goserelin acetate • Zynyz (retifanlimab-dlwr) • fludarabine IV • Ostarine (enobosarm) • avadomide (CC-122) • vistusertib (AZD2014) • Myocet (non-pegylated liposomal doxorubicin) • mesna • vinblastine • Xofigo (radium Ra-223 dichloride) • lorvotuzumab mertansine (IMGN901) • Ampligen (rintatolimod) • E6201 • Fujovee (abivertinib) • Paletan (pertuzumab biosimilar) • Provenge (sipuleucel-T) • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • CC-90002 • EG1206A (pertuzumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • ImmuniCell (autologous γδ T lymphocytes) • Leukine (sargramostim) • Pertuvia (pertuzumab biosimilar) • Vasforda (bevacizumab biosimilar) • celecoxib oral • cyclophosphamide intravenous • dexamethasone injection • ieramilimab (LAG525) • levoleucovorin calcium • methotrexate IV • sapitinib (AZD8931)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6452","initiation":"Initiation: 08/17/2015","start_date":" 08/17/2015","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2025-02-06"},{"id":"b94d473a-a828-47ba-9b4c-363678434e70","acronym":"PDIGREE","url":"https://clinicaltrials.gov/study/NCT03793166","created_at":"2021-01-18T18:45:15.236Z","updated_at":"2025-02-25T16:44:31.244Z","phase":"Phase 3","brief_title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","source_id_and_acronym":"NCT03793166 - PDIGREE","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 1175","initiation":"Initiation: 06/07/2019","start_date":" 06/07/2019","primary_txt":" Primary completion: 09/15/2025","primary_completion_date":" 09/15/2025","study_txt":" Completion: 09/15/2025","study_completion_date":" 09/15/2025","last_update_posted":"2025-02-06"},{"id":"78abffa2-7b4c-493d-a391-404776dd9c0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01038778","created_at":"2021-01-18T04:04:38.458Z","updated_at":"2025-02-25T16:58:23.955Z","phase":"Phase 1/2","brief_title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","source_id_and_acronym":"NCT01038778","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" mTOR","pipe":"","alterations":" ","tags":["mTOR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Jingzhuda (entinostat) • Proleukin (aldesleukin)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 47","initiation":"Initiation: 10/29/2009","start_date":" 10/29/2009","primary_txt":" Primary completion: 05/22/2019","primary_completion_date":" 05/22/2019","study_txt":" Completion: 07/30/2025","study_completion_date":" 07/30/2025","last_update_posted":"2025-02-03"},{"id":"3339f750-4360-456a-b1ee-c276f0735a58","acronym":"","url":"https://clinicaltrials.gov/study/NCT03473730","created_at":"2021-01-18T17:07:06.521Z","updated_at":"2025-02-25T17:29:38.839Z","phase":"Phase 1","brief_title":"Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer","source_id_and_acronym":"NCT03473730","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Darzalex (daratumumab)"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 05/29/2018","start_date":" 05/29/2018","primary_txt":" Primary completion: 01/27/2025","primary_completion_date":" 01/27/2025","study_txt":" Completion: 01/27/2025","study_completion_date":" 01/27/2025","last_update_posted":"2025-01-30"},{"id":"80d5522f-7e62-4840-9814-99046b8adfc5","acronym":"DEKA-1","url":"https://clinicaltrials.gov/study/NCT05704985","created_at":"2023-01-30T15:59:33.980Z","updated_at":"2025-02-25T17:31:52.518Z","phase":"Phase 1","brief_title":"Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors","source_id_and_acronym":"NCT05704985 - DEKA-1","lead_sponsor":"DEKA Biosciences","biomarkers":" EGFR • IL2 • IL10","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 04/03/2023","start_date":" 04/03/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2025-01-23"},{"id":"163ac97d-61c1-4dda-8fa6-429e5d0086da","acronym":"","url":"https://clinicaltrials.gov/study/NCT06762925","created_at":"2025-02-26T07:20:20.648Z","updated_at":"2025-02-26T07:20:20.648Z","phase":"","brief_title":"Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment","source_id_and_acronym":"NCT06762925","lead_sponsor":"Xijing Hospital","biomarkers":" METTL3","pipe":"","alterations":" ","tags":["METTL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 450","initiation":"Initiation: 01/30/2025","start_date":" 01/30/2025","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-08"},{"id":"6ebd48e9-5936-4d43-8216-9384c42cf063","acronym":"","url":"https://clinicaltrials.gov/study/NCT06680089","created_at":"2025-02-26T12:33:05.578Z","updated_at":"2025-02-26T12:33:05.578Z","phase":"","brief_title":"CD70-targeted immunoPET Imaging of Kidney Cancer","source_id_and_acronym":"NCT06680089","lead_sponsor":"RenJi Hospital","biomarkers":" CD70","pipe":"","alterations":" ","tags":["CD70"],"overall_status":"Recruiting","enrollment":" Enrollment 300","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2024-11-22"},{"id":"7a194544-769d-4908-bc9c-7b8bbff6762b","acronym":"NCI-2012-01247","url":"https://clinicaltrials.gov/study/NCT01684397","created_at":"2023-11-30T22:15:06.234Z","updated_at":"2025-02-25T13:17:55.736Z","phase":"Phase 1/2","brief_title":"Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer","source_id_and_acronym":"NCT01684397 - NCI-2012-01247","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" CXCL8","pipe":"","alterations":" ","tags":["CXCL8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • pazopanib"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 11/21/2012","start_date":" 11/21/2012","primary_txt":" Primary completion: 05/02/2025","primary_completion_date":" 05/02/2025","study_txt":" Completion: 05/02/2025","study_completion_date":" 05/02/2025","last_update_posted":"2024-11-06"},{"id":"b4088fdb-ec50-47ff-acf6-df6ef4b30a62","acronym":"TAZNI","url":"https://clinicaltrials.gov/study/NCT05407441","created_at":"2022-06-07T22:59:09.709Z","updated_at":"2025-02-25T14:17:01.156Z","phase":"Phase 1/2","brief_title":"Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors","source_id_and_acronym":"NCT05407441 - TAZNI","lead_sponsor":"Susan Chi, MD","biomarkers":" SMARCB1","pipe":" | ","alterations":" SMARCA4 mutation","tags":["SMARCB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Tazverik (tazemetostat)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 08/10/2023","start_date":" 08/10/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-09-13"},{"id":"aff3e72a-a029-43e5-b059-ba3db87de101","acronym":"","url":"https://clinicaltrials.gov/study/NCT05127824","created_at":"2021-11-19T12:53:43.443Z","updated_at":"2024-07-02T16:34:26.105Z","phase":"Phase 2","brief_title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","source_id_and_acronym":"NCT05127824","lead_sponsor":"Jodi Maranchie","biomarkers":" ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5","pipe":"","alterations":" ","tags":["ER • CD8 • PD-1 • IFNG • LAG3 • TIGIT • LAMP3 • GZMB • BTLA • CD31 • NRP1 • PECAM1 • ANXA5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • aDC1 vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 07/06/2023","start_date":" 07/06/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-14"},{"id":"eb48e074-c9c1-4740-b335-db17f9ac4451","acronym":"PAPMET","url":"https://clinicaltrials.gov/study/NCT02761057","created_at":"2024-02-04T01:56:06.891Z","updated_at":"2024-07-02T16:34:26.084Z","phase":"Phase 2","brief_title":"Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed","source_id_and_acronym":"NCT02761057 - PAPMET","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET","pipe":" | ","alterations":" MET mutation • MET expression","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET mutation • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • sunitinib • Cabometyx (cabozantinib tablet) • Orpathys (savolitinib) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 152","initiation":"Initiation: 07/25/2016","start_date":" 07/25/2016","primary_txt":" Primary completion: 10/02/2023","primary_completion_date":" 10/02/2023","study_txt":" Completion: 12/12/2024","study_completion_date":" 12/12/2024","last_update_posted":"2024-06-14"},{"id":"d3894fe7-c2a5-46ce-9212-204653c06726","acronym":"","url":"https://clinicaltrials.gov/study/NCT00033137","created_at":"2021-01-18T00:01:03.867Z","updated_at":"2024-07-02T16:34:26.356Z","phase":"","brief_title":"Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer","source_id_and_acronym":"NCT00033137","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" FLCN","pipe":"","alterations":" ","tags":["FLCN"],"overall_status":"Recruiting","enrollment":" Enrollment 950","initiation":"Initiation: 05/13/2002","start_date":" 05/13/2002","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2024-06-13"},{"id":"795a3eed-60a1-4800-a0cc-df6e4a85200a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05665361","created_at":"2022-12-27T14:58:35.799Z","updated_at":"2024-07-02T16:34:58.850Z","phase":"Phase 1/2","brief_title":"Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)","source_id_and_acronym":"NCT05665361","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Zumrad (sasanlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 04/24/2024","start_date":" 04/24/2024","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-06-05"},{"id":"64411eb8-6d74-4c88-b0b8-fb08d1f38b31","acronym":"","url":"https://clinicaltrials.gov/study/NCT02210117","created_at":"2021-01-18T10:21:09.236Z","updated_at":"2024-07-02T16:34:59.480Z","phase":"Phase 1","brief_title":"Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery","source_id_and_acronym":"NCT02210117","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IL17A","pipe":"","alterations":" ","tags":["IL17A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • Beianting (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 11/25/2014","start_date":" 11/25/2014","primary_txt":" Primary completion: 11/30/2025","primary_completion_date":" 11/30/2025","study_txt":" Completion: 11/30/2025","study_completion_date":" 11/30/2025","last_update_posted":"2024-06-03"},{"id":"84572fdb-bb5f-45fd-aa5f-f18dedb5e9a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05334069","created_at":"2022-04-19T23:53:56.743Z","updated_at":"2024-07-02T16:35:01.625Z","phase":"","brief_title":"Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection","source_id_and_acronym":"NCT05334069","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" MUC16","pipe":" | ","alterations":" MUC16 elevation","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MUC16 elevation"],"overall_status":"Recruiting","enrollment":" Enrollment 2000","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-05-23"},{"id":"28905f7c-1ba3-4c54-b0ee-8bfef8ba9fd0","acronym":"CDFF332A12101","url":"https://clinicaltrials.gov/study/NCT04895748","created_at":"2021-05-20T11:54:08.339Z","updated_at":"2024-07-02T16:35:03.755Z","phase":"Phase 1","brief_title":"DFF332 as a Single Agent and in Combination With Everolimus \u0026 Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer \u0026 Other Malignancies","source_id_and_acronym":"NCT04895748 - CDFF332A12101","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2","pipe":" | ","alterations":" VHL mutation • SDHB mutation","tags":["VHL • SDHB • EPAS1 • SDHC • SDHD • SDHA • SDHAF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation • SDHB mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • spartalizumab (PDR001) • DFF332 • taminadenant (NIR178)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/30/2021","start_date":" 11/30/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 02/28/2025","study_completion_date":" 02/28/2025","last_update_posted":"2024-05-14"},{"id":"80ae9b9a-9383-4fbe-a030-18f6cfe6115b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03798626","created_at":"2021-01-18T18:47:09.510Z","updated_at":"2024-07-02T16:35:03.688Z","phase":"Phase 1","brief_title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","source_id_and_acronym":"NCT03798626","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-14"},{"id":"3c7531a5-d2c1-4a20-9990-f4c698763dbe","acronym":"SPARTA","url":"https://clinicaltrials.gov/study/NCT03175224","created_at":"2022-05-11T08:56:01.997Z","updated_at":"2024-07-02T16:35:04.401Z","phase":"Phase 2","brief_title":"APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors","source_id_and_acronym":"NCT03175224 - SPARTA","lead_sponsor":"Apollomics Inc.","biomarkers":" HGF • PTPRZ1","pipe":" | ","alterations":" EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion","tags":["HGF • PTPRZ1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • MET amplification • EGFR wild-type • MET exon 14 mutation • MET overexpression • MET expression • EGFR positive • MET fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vebreltinib (APL-101) • CBT101"],"overall_status":"Recruiting","enrollment":" Enrollment 497","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 03/30/2026","primary_completion_date":" 03/30/2026","study_txt":" Completion: 11/30/2026","study_completion_date":" 11/30/2026","last_update_posted":"2024-05-10"},{"id":"a5409d19-a682-484b-8074-dbc0380cdead","acronym":"","url":"https://clinicaltrials.gov/study/NCT02601950","created_at":"2021-01-17T17:38:36.460Z","updated_at":"2024-07-02T16:35:07.229Z","phase":"Phase 2","brief_title":"A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma","source_id_and_acronym":"NCT02601950","lead_sponsor":"Epizyme, Inc.","biomarkers":" CD34 • SS18","pipe":" | ","alterations":" SMARCA4 mutation","tags":["CD34 • SS18"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SMARCA4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tazverik (tazemetostat)"],"overall_status":"Completed","enrollment":" Enrollment 267","initiation":"Initiation: 12/22/2015","start_date":" 12/22/2015","primary_txt":" Primary completion: 02/26/2024","primary_completion_date":" 02/26/2024","study_txt":" Completion: 02/26/2024","study_completion_date":" 02/26/2024","last_update_posted":"2024-04-29"}]